共 50 条
- [35] Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (01): : 28 - 37
- [36] Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (03): : 210 - 221
- [39] The impact of biological interventions for ulcerative colitis on health-related quality of life COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (09):